Investors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so ...

Moderna's melanoma mRNA vaccine had a major Phase 3 breakthrough. Here's what's next and when it could become available for skin cancer patients.

As the dust settles on a phase 3 announcement that added $45 billion to Moderna’s market cap, analysts have begun to ask a question that could define cancer care in the coming years: can use of the ...

A personalized mRNA cancer vaccine combined with the immunotherapy Keytruda succeeded in a late-stage trial for the deadly skin cancer melanoma, its makers said<a class="excerpt-read-more" href=" More ...

Moderna and Merck have been running a large Phase III trial in over a thousand high-risk patients who had already had surgery ...

The company’s fortunes cratered as demand for Covid-19 vaccines plummeted. But it was busy working on something else.

A breakthrough melanoma vaccine is making headlines. But can patients get it yet? Here's where FDA approval stands.

Moderna shares pulled back sharply on Thursday, giving up a small chunk of Wednesday’s record-breaking rally after the stock rocketed as much as 177% on data showing its personalized cancer vaccine, ...

Moderna stock surged on Phase 3 mRNA cancer vaccine results with Merck, breaking key moving averages and hitting record RSI.

Adding the personalized mRNA therapy intismeran autogene to Keytruda cut melanoma recurrence and spread risk after surgery, a Phase 3 trial found. A Phase 3 trial found that adding the individualized ...

Moderna's personalised mRNA cancer vaccine uses a patient's tumour genetics to train the immune system, enabling it to ...

In August 2026, Merck and Moderna reported that their Phase 3 INTerpath-001 trial showed that individualized mRNA therapy ...